These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 23687781)

  • 1. Fifteen years of anti-HER2 therapy.
    Davidson NE
    Oncology (Williston Park); 2013 Mar; 27(3):151. PubMed ID: 23687781
    [No Abstract]   [Full Text] [Related]  

  • 2. Next-generation targeted agents in HER2-positive metastatic breast cancer.
    Perez EA
    Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288
    [No Abstract]   [Full Text] [Related]  

  • 3. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
    Esteva FJ; Pusztai L
    Oncology (Williston Park); 2005 Nov; 19(13 Suppl 5):4. PubMed ID: 19364050
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
    Morris SR; Carey LA
    Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ado-trastuzumab emtansine (Kadcyla) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2013 Sep; 55(1425):75-6. PubMed ID: 24662957
    [No Abstract]   [Full Text] [Related]  

  • 7. HER2 inhibition: from discovery to clinical practice.
    Chang JC
    Clin Cancer Res; 2007 Jan; 13(1):1-3. PubMed ID: 17200331
    [No Abstract]   [Full Text] [Related]  

  • 8. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2-directed therapy for metastatic breast cancer.
    Jelovac D; Emens LA
    Oncology (Williston Park); 2013 Mar; 27(3):166-75. PubMed ID: 23687784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance to HER2 target therapy.
    Tortora G
    J Natl Cancer Inst Monogr; 2011; 2011(43):95-8. PubMed ID: 22043051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future anti-HER2 therapy in breast cancer.
    Vrbic S; Pejcic I; Filipovic S; Kocic B; Vrbic M
    J BUON; 2013; 18(1):4-16. PubMed ID: 23613383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How can we optimize treatment of HER2-positive metastatic breast cancer?
    Hamilton EP; Blackwell KL
    Oncology (Williston Park); 2013 Mar; 27(3):180, 182. PubMed ID: 23687786
    [No Abstract]   [Full Text] [Related]  

  • 13. HER2-directed treatment of metastatic breast cancer: unanswered questions.
    Rao R; Cobleigh M
    Oncology (Williston Park); 2013 Mar; 27(3):176, 178, 180. PubMed ID: 23687785
    [No Abstract]   [Full Text] [Related]  

  • 14. Improving treatment of HER2-positive cancers: opportunities and challenges.
    Stern HM
    Sci Transl Med; 2012 Mar; 4(127):127rv2. PubMed ID: 22461643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-positive breast cancer: beyond trastuzumab.
    Murphy CG; Fornier M
    Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
    Roukos DH
    J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
    [No Abstract]   [Full Text] [Related]  

  • 17. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
    Yamashita T; Iwata K
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
    [No Abstract]   [Full Text] [Related]  

  • 18. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.
    Bedard PL; Piccart-Gebhart MJ
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S157-65. PubMed ID: 19158036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib.
    Moy B; Kirkpatrick P; Kar S; Goss P
    Nat Rev Drug Discov; 2007 Jun; 6(6):431-2. PubMed ID: 17633789
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
    Nielsen DL; Kümler I; Palshof JA; Andersson M
    Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.